Thank [ this morning. Steph for thank ], everybody, you, you, joining and
present XXXX. go for financial fiscal third ended December excited quarter XX, I'm quarter to to Yes, pleased I'm our you, together. thank results to get
a be frankly, we've had update will relatively This because, quarter. shorter a very busy
X last quarterly we last published well. a our together. a to then results week believe, hard RVT-XXXX had as to call but in-licensed It's ago. or we've was did certain so We've get And it after a when of for financing, few we opportunities taken that fiscal weeks data actually, preannounced and update we
updates in some looking the everybody, sharing forward you, of some VTAMA. interesting updates thank particular, and share to launch commercial again, around and have to So
quickly X, XXXX. So on I'm everybody still it's in to out reminding early because Slide just start going
data year. announcement The antibody for off our RVT-XXXX about excited strong of induction the the phase ongoing ] year study. data, of us from our [ the IIb We in are started our very this Phase for anti-TLXA
a payor course year, important more which expect to the yields coverage and business, continued translate, of to scripts. really over this including reach continue time from to and we'll talk updates number over the of across We of VTAMA, improve gross literally expect we and today about -- net
X We can the to we now XXXX expect in enrolled, from X X dermatitis of March top X data say ADORING fully line both studies ADORING ADORING are and atopic and studies ADORING of XXXX. share from in May those and
AD up is our as very this, [ -- more size it which the about psoriasis. a we'll little ] from coming in data program soon, market where bit important we're Xx currently the exciting opens So the of market talk
] anti-TLXA for the expect that year XX-week trial, of than important is our antibody. half, to from think we We right middle first [ think the meaningful beginning, an the the RVT-XXXX, reported the the data, dosing time data. chronic antibody, from data closer in anti-TLXA We first anyone's XX-week the data period of which
it's available. when So we're set that full sharing looking to data forward
franchise we with [indiscernible]. with maximal us human of best I -- the as have least potentially our well IgG if the X watching, IMVT-XXXX which potentially best data of middle in as with anti-FcRn on In many successful, we this drugs, antibody are anti-FcRn the no year, think impact as know leave next-generation at suppression from the will, IMVT-XXXX, category, will both
what potential TYKX really expect pivotal and best as about of in some before, we the the talked JAKX, announcements has And to of SLE, the to we've in pivotal X year, data with then our from we of quarter X which seen finally, potential data brepocitinib this in SLE. produce studies among be major the fourth in dual-inhibitor
it. got we've when data that share to excited So
on start So to on for. commercial just financial results. be I'll I'm with incredibly just of launch we start the brief which with with excited update continue And going today of that, to X VTAMA, the a an review
updates we revenue now last at disclosed for And week, report, early near think first I the moment. of in with And in in gross launch, -- our Some about quarter already yield our and in revenues of ended. one of I'm quarter, to doubling particularly from in a the as we'll $X.X improvements just I XX% second to XX% seen net our thing quarter we've talk happy quarter this, to up mentioned, launch. payor million a
number see time improve payor continued that I updates, expect with over we here. to think continue to
the physician and really product. are the for patient with We happy demand continued level of
We or demand really across less you'll had our a and the ongoing continue conversations. the get positive as to -- impact board, great payor a on feedback see more
share really So about how going is and to as updates that yes, get in to ]. excited that we launch the excited calendar year [ continue into
the branded be #X Slide On to we topical. X, continue
a trajectory yes, since after been bit as the what script with enthusiasm we the to holidays. for excited have see just here excited are little really we forward. from with around for launch payor doc week at optimistic choppiness look eighth the our and We're and volumes We return enthusiasm. to mean patients of growth, And
vast a our in topical number even this IMS, launch. we are scripts, are remember beginning But most I on slide. great In showed for because and steroids. often X,XXX This stage the -- majority the equally right? which slide XX,XXX is disclosed perhaps that I most topical recent week, recently for really Slide just it's every IMS this think prescriptions alone, the us, is great there which X of psoriasis did But about of disclose a pretty --
tolerated. safer steroids. in which have our both get a as a that data little every atopic there our better topical And XXX,XXX of dermatitis us topical well population, once conclusively, in efficacious and psoriasis, than majority vast again, are are with remitted access prescriptions establishes And patient as more we to our as view, data and benefit dermatitis over the corticosteroids atopic week, meaningfully
profile to very, those sharing forward and dermatitis continuing very that will and large forward to on opportunities. push into atopic to dials to the grow looking allow looking levers that So us
been a Dermavant the It's team. of solid execution for quarter
trials X with XXXX I As those again, before, first ADORING both in March expected the ADORING one, and atopic dermatitis in May. readouts expected, fully [indiscernible] are expected enrolled. mentioned X And
So important clinical data coming. And access. to we continue high formulary quality expand
maybe update And well. on as an provide on just I'll Slide XX that
X commercial XX% million First national VTAMA. a we we review to at actually of ahead health lines Cross ]. covered coverage have all, for across of close of new-to-market of so that point, say, X I'm XX includes lives, block X Blue [ PBM its PBM X Shield X an good this pleased plans, formulary, addition Blue that formulary, and PBM that plans, regional national to have lifted That's those national lives
and in medical are enthusiastic cases, VTAMA profile so these progress of to are we're about coverage. led it So good patients being by decisions on the many who really that making the payors offers teams medical these what of really,
I a have the say, physician demand; progress, have Slide clinical of XX, the driven think, drive examples the lot work a look, in coverage. judgment, and from of of teams factors patient team. mentioned, And front on of a on home medical including and of this I volumes, prescription ton as our hard sort value value I'd I multiple point -- overall payor of that couple around quality
examples. representative Some
only single a major edit topical a the and Vitamin lifted PBMs of the new-to-market D. block a step to requires One or
X, Another major us PBM topical through D and or formulary a combination. requires steroid, added to step either Vitamin a a
at all. has with restrictions, edits no PBM added VTAMA steps or regional A
covers X with unrestricted back. -- parity recently -- of on with a I'll of branded sort and topical us there's national plan common a regional a small plans plan and plans us therapies. generic small effect, product. simple a so four And And that far, any look in add completely sorry, many ahead regional of other steroid health with X VTAMA as preferred competitors is cover So through steroids. X small as or launched step has the VTAMA regional but this plan, any most actually Two cover topical a
high-quality question and which an happy coverage, at to strategy achieved strategy are of the strategies we access to are PBM overall, at access. or pricing And how pricing you'll around, in And around amount has cases, a important remember, are pleased only topical because was I'll there And we're happy not the some PBM on a market the better coverage going better -- no consistently now really are pricing payor by around are covered competitors. last fair we about definitely really advantage by plan, parity and overall. are that's we here our discussions than of different strategy early our and at drive with thing report say and is, we sort discussion disadvantage was very we plan that
payor progress really, with happy really So the here.
from this how GTN yield have deductible of some more calendar of the progresses, difficult shown sometimes same. our analogous good As quarter show is over because of little progress the indications first competitors a as to time. expect the bit far a year I Candidly, perspective in resets.
more economics head you'll I quarter and P&L, can second before, up excited broad contracts. but now coming attractive we've the going I towards we're things as think understanding commercial -- that in with So see those coverage an start progress give really beyond, of for to an to and developments and that those back said of
it on execution. in but clinical I'll Q&A sure VTAMA, there So on the I'll and move I'm to questions get some on stop
multiple XXXX. data that set So are company. each fact, than and beyond XX We readouts, coming point, I&I first more we're coming a didn't multiple about go sort II have all, XX of Slide observation But of and Phase to building we the XX, data this in -- or on including have at just really approvals we immunology readouts, franchise new high-level excited readouts registrational III a -- each number build interesting between I&I. now and year of inflammation here. And year an as out opportunities readouts we
progress massive the of couple over So years. next
Obviously, with franchise about in large beyond, think leads, that building we XXXX lot we aggregate additional peak talked more XXXX has or a $XX billion high potential. need. indications unmet across of That an potential approvals earlier. data And wave the to I&I towards from a revenue I&I
So just and TYKX/JAKX for as franchise and this our other that. VTAMA remember, a and FcRn And as opportunity TLXA, huge programs behind spans well us.
franchises, quarters forward, [ most and this what this the think see build from we many excited we're year. one of I&I biotech this we and did So we're interest lots exciting ] of excited to of to is different
late-stage data of updates going talking in to and VTAMA many I a spend the before. talk for RVT-XXXX More about the You see important come was of portfolio in can looking programs data as it on a review familiar this the amount But earlier them coming too of not say beyond we're Roivant, today. that excited all is Slide as the least will that for much I'm about us. these pipeline clinical later. sharing XX. coming at have high-quality unprecedented, We'll second. imminently today. of they to year discussed I And time and for is forward really
and anti-TLXA have just data or going to to first lead many it's going [indiscernible] it's proud over believe our am only it's new and to bit and us an we that's of ago, and before, watched out I this hard put of story. this, actually -- because just what review do so closely to the a So RVT-XXXX but heard still a briefly, I been antibody I'm month for to but still you know area little it's it it.
antibody currently other plan indications. delivered This reminder, it. colitis developing has we and as specific is really to for It's Crohn's So class data. some in extraordinary excited anti-TLXA data Phase which RVT-XXXX and ulcerative and develop III-ready that a are we disease a agents in our are about
run tolerability benefit data highest-end to partner, use benefit in rates And a had enrich meaningful were our explored well. the statistically that a all we tested. covers doses subset. profile biomarker, response the across lot Pfizer identified of as was that a prospectively overall, population specific patient and to clinical biomarker, with -- XX% and of a which II meaningful We further we the optimize able biomarkers had a were that all-comers great of this in an Some choice we have biomarker to Phase Remember UC different meaningful prospectively of study able safety clinically efficacy defined population.
largest be Phase should in large is ever potentially this run first-in-class the one This think agent markets. well-validated studies We colitis. ulcerative of and the IIb in
the our first IIa that Phase chronic have XXX data in we IIb an our for between phase. before, patients the IIb this study coming half We dosed Phase and important study. Phase mentioned And year I near-term of have catalyst this dosing
got of important TLXA, fibrotic is a operation, on mechanism it's pretty really of a mode amplifier sort whole cool that's signal Slide where pro-inflammatory for a a different bunch and different a reminder, XX, of as cytokines.
it's and associated got the on multiple bit pulmonary meaningful -- pathway, action as pipeline real markers their frankly which fibrotic a unique our inflammatory drug. these as fibrosis. of on a we've diseases mechanism Crohn's parts the beyond supports in with profile. liver of some blue And across so a sort that of different fibrotic clinical data the fibrosis, opportunities Phase safety that of that seen as quality well UC multiple both of UC fibrosis, clinical thinking the of data with are intestinal the with and of Pfizer showed publications sort quality as as encourages little and impact the data given well And a is sky inflammatory the And IIa with well diseases, reminder, of the a impact other quality
So a XX% population starting that I we look, And our supported with placebo-adjusted efficacy always rate which Slide biomarker III Great XX a showed our placebo-adjusted that a from excited class. well. XX% that with the just agent data is difficult data all-comers class seen any the data across the of -- at both again, And We gross competitor remission to and efficacy is data or the then endoscopic are dose on some our population. with is most were incredibly patients biomarker, delta XX% activity, remind to and clinical on that a very a efficacy on across best compelling of seen the the sets for able just in as Phase XX, best about Slide preserve everyone gross delta in of by here. one improvement and placebo-adjusted we biologic-experienced in or XX% XX expected population. gross delta
real to Most or that get patient a some many possibilities, second agent second-line cases, you respond therapies, this biomarker, extraordinary significant other efficacy longer line. for second-line of opens breadth population. is, opportunity sick a multiple have And patient classes this no patients, once over data really is become including This choice. of the of population our up fall drugs given an us of to degradation population. Placebo in in into
for for So this help therapy. comers. to all going from this to opportunity couples, dose. placebo-like We're we're perspective, see to but going certainly our remarkably the nothing drug than patients sort label almost to expected profile develop second-line our of really III with being, at biomarker a an we are less with Phase Slide of frankly, in XX, just develop pool category every safety excited And on and a with both or all placebo the no
going now. to you I'm not it a about so so about data. And talk talked see can We've lot here before, of it
to on it. have questions also take I'll
that, profile as data the both our at placebo with we on looking hold be will and maintenance and well we've in preliminary there. inter-analysis immunogenicity about based relationship We fact seen relationship see when safety up as continue efficacy to the and that the confident the
to open give that, just programs talk financial the a with the going We're then business to other not today. clinical update about update, So going Q&A. portion I'm of to and more end going I'm and this. brief we'll to line
expected cash We cash of proceeds well adjusted quarter from notably, we GAAP SG&A quarter Dermavant position or of the to to the minority Sumitomo We with with expense, and sale $XXX have this as effect the expense, $XXX complete we million. million as and we quarter. We of majority that the that million. equivalents VTAMA. So develop. about we And again, very balance ended non-GAAP billion billion then Myovant or ago the $X.X of the had X discussed. see did SG&A continue to associated launch giving to weeks sheet adjusted of financially $XXX from $X.X which expense of expect And of cash the $XXX we strong million GAAP Pharma, or a a to financing good comes as had R&D of
us, So second before, half XXXX. as of gives runway the we've look, that cash into discussed
across ability data produce important speed confident tremendous I've the that all and programs did are during I'm multiple the of us us a clinical We will full that we clinical at run to XXXX, other just including important makes only producing for amount data weeks XXXX some window. a the in The of programs across programs during we financing of couple gives period mentioned. a ago --
So really over looking financial taking now done we're the last XX-K with to provide position I continue work bunch looking forward questions file this your all proud has the that between updates team of happy a when quarter, updates. in, Roivant and our those to and forward and sharing later feel we year. to that the obviously of
after everybody. over thank with I'll to to the go that brief So Q&A. it to for morning. Thanks time that, operator this session, you, turn And the
